TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, via a share buy settlement. Juno GmbH was beforehand owned by Bristol Myers Squibb. Monetary phrases haven’t been disclosed. The acquisition expands TQx’s entry to mental property and licensing agreements that can assist the event of its decentralised, automated cell […]
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, via a share buy settlement. Juno GmbH was beforehand owned by Bristol Myers Squibb. Monetary phrases haven’t been disclosed.
The acquisition expands TQx’s entry to mental property and licensing agreements that can assist the event of its decentralised, automated cell and gene remedy (CGT) platform. The corporate is advancing a bedside-compatible system designed to scale back manufacturing instances and enhance scalability in extracorporeal cell remedy.
“This acquisition allows us to speed up growth of our ultra-short CGT platform,” stated Christian Eckert, CEO of TQx. “It helps our objective of creating superior therapies extra accessible and cost-effective.”
TQx is concentrated on remodeling cell remedy manufacturing by transferring away from centralised infrastructure towards on-site processing. Its platform is designed to ship individualised therapies with diminished logistical and operational burden.
Juno GmbH beforehand operated as a part of Bristol Myers Squibb’s European cell remedy portfolio. TQx has not disclosed operational integration plans following the acquisition.
The deal kinds a part of TQx’s technique to advance applied sciences that broaden entry to CGT therapies throughout a wider vary of healthcare settings.
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, via a share buy settlement. Juno GmbH was beforehand owned by Bristol Myers Squibb. Monetary phrases haven’t been disclosed. The acquisition expands TQx’s entry to mental property and licensing agreements that can assist the event of its decentralised, automated cell […]
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, via a share buy settlement. Juno GmbH was beforehand owned by Bristol Myers Squibb. Monetary phrases haven’t been disclosed.
The acquisition expands TQx’s entry to mental property and licensing agreements that can assist the event of its decentralised, automated cell and gene remedy (CGT) platform. The corporate is advancing a bedside-compatible system designed to scale back manufacturing instances and enhance scalability in extracorporeal cell remedy.
“This acquisition allows us to speed up growth of our ultra-short CGT platform,” stated Christian Eckert, CEO of TQx. “It helps our objective of creating superior therapies extra accessible and cost-effective.”
TQx is concentrated on remodeling cell remedy manufacturing by transferring away from centralised infrastructure towards on-site processing. Its platform is designed to ship individualised therapies with diminished logistical and operational burden.
Juno GmbH beforehand operated as a part of Bristol Myers Squibb’s European cell remedy portfolio. TQx has not disclosed operational integration plans following the acquisition.
The deal kinds a part of TQx’s technique to advance applied sciences that broaden entry to CGT therapies throughout a wider vary of healthcare settings.
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, via a share buy settlement. Juno GmbH was beforehand owned by Bristol Myers Squibb. Monetary phrases haven’t been disclosed. The acquisition expands TQx’s entry to mental property and licensing agreements that can assist the event of its decentralised, automated cell […]
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, via a share buy settlement. Juno GmbH was beforehand owned by Bristol Myers Squibb. Monetary phrases haven’t been disclosed.
The acquisition expands TQx’s entry to mental property and licensing agreements that can assist the event of its decentralised, automated cell and gene remedy (CGT) platform. The corporate is advancing a bedside-compatible system designed to scale back manufacturing instances and enhance scalability in extracorporeal cell remedy.
“This acquisition allows us to speed up growth of our ultra-short CGT platform,” stated Christian Eckert, CEO of TQx. “It helps our objective of creating superior therapies extra accessible and cost-effective.”
TQx is concentrated on remodeling cell remedy manufacturing by transferring away from centralised infrastructure towards on-site processing. Its platform is designed to ship individualised therapies with diminished logistical and operational burden.
Juno GmbH beforehand operated as a part of Bristol Myers Squibb’s European cell remedy portfolio. TQx has not disclosed operational integration plans following the acquisition.
The deal kinds a part of TQx’s technique to advance applied sciences that broaden entry to CGT therapies throughout a wider vary of healthcare settings.
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, via a share buy settlement. Juno GmbH was beforehand owned by Bristol Myers Squibb. Monetary phrases haven’t been disclosed. The acquisition expands TQx’s entry to mental property and licensing agreements that can assist the event of its decentralised, automated cell […]
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, via a share buy settlement. Juno GmbH was beforehand owned by Bristol Myers Squibb. Monetary phrases haven’t been disclosed.
The acquisition expands TQx’s entry to mental property and licensing agreements that can assist the event of its decentralised, automated cell and gene remedy (CGT) platform. The corporate is advancing a bedside-compatible system designed to scale back manufacturing instances and enhance scalability in extracorporeal cell remedy.
“This acquisition allows us to speed up growth of our ultra-short CGT platform,” stated Christian Eckert, CEO of TQx. “It helps our objective of creating superior therapies extra accessible and cost-effective.”
TQx is concentrated on remodeling cell remedy manufacturing by transferring away from centralised infrastructure towards on-site processing. Its platform is designed to ship individualised therapies with diminished logistical and operational burden.
Juno GmbH beforehand operated as a part of Bristol Myers Squibb’s European cell remedy portfolio. TQx has not disclosed operational integration plans following the acquisition.
The deal kinds a part of TQx’s technique to advance applied sciences that broaden entry to CGT therapies throughout a wider vary of healthcare settings.
